Erythropoietic Protoporphyria Clinical Trial
Official title:
A Phase II, Multicentre, Double-Blind, Randomised, Placebo-Controlled Study to Confirm the Safety and Efficacy of Subcutaneous Bioresorbable Afamelanotide Implants in Patients With Erythropoietic Protoporphyria (EPP)
NCT number | NCT01097044 |
Other study ID # | CUV030 |
Secondary ID | |
Status | Completed |
Phase | Phase 2 |
First received | |
Last updated | |
Start date | April 2010 |
Est. completion date | April 2011 |
Verified date | October 2019 |
Source | Clinuvel Pharmaceuticals Limited |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a randomized placebo-controlled study to be conducted in two parallel study arms for
a six month period (three doses). Approximately 10 eligible patients per center will be
enrolled and will receive afamelanotide (16 mg implants) or placebo according to the
following dosing regimen:
- Group A will be administered afamelanotide implants on Days 0, 60 and 120
- Group B will be administered placebo implants on Days 0, 60 and 120
To determine eligibility for study inclusion, patients will undergo a screening evaluation 7
to 14 days prior to the administration of the first dose. The number and severity of
phototoxic reactions will be determined Days 60, 120, and 180. Quality of life will be
measured using the EPP specific questionnaire (EPP-QoL) every 60 days and the DLQI
questionnaire every 7 days, beginning at Day 0 until Day 180. Participants will visit the
clinic on Days 60, 120 and 180 for assessments of adverse events.
Status | Completed |
Enrollment | 77 |
Est. completion date | April 2011 |
Est. primary completion date | April 2011 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Male or female subjects with characteristic photosensitivity of EPP symptoms and positive diagnosis of EPP confirmed by laboratory result of elevated total protoporphyrin IX. - Aged 18 years old and above (inclusive). - Able to understand and sign the written Informed Consent Form. - Willing to take precautions to prevent pregnancy until completion of the study (Day 180). Exclusion Criteria: - Any allergy to afamelanotide or the polymer contained in the implant or to lidocaine or other local anesthetic to be used during the administration of the study medication - EPP patients with significant hepatic involvement - Personal history of melanoma or dysplastic nevus syndrome. - Current Bowen's disease, basal cell carcinoma, squamous cell carcinoma, or other malignant or premalignant skin lesions. - Any other photodermatosis such as PLE, DLE or solar urticaria. - Any evidence of clinically significant organ dysfunction or any clinically significant deviation from normal in the clinical or laboratory determinations. - Acute history of drug or alcohol abuse (in the last 6 months). - Patient assessed as not suitable for the study in the opinion of the Investigator (e.g. noncompliance history, allergic to local anesthetics, faints when given injections or giving blood). - Participation in a clinical trial for an investigational agent within 30 days prior to the screening visit. - Prior and concomitant therapy with medications which may interfere with the objectives of the study, including drugs that cause photosensitivity or skin pigmentation within 60 days prior to the screening visit. - Female who is pregnant (confirmed by positive serum ß-HCG pregnancy test prior to baseline) or lactating. - Females of child-bearing potential (pre-menopausal, not surgically sterile) not using adequate contraceptive measures (i.e. oral contraceptives, diaphragm plus spermicide, intrauterine device). |
Country | Name | City | State |
---|---|---|---|
United States | University of Alabama | Birmingham | Alabama |
United States | Carolina's Medical Center Cannon Research | Charlotte | North Carolina |
United States | University of Texas | Galveston | Texas |
United States | Mt. Sinai | New York | New York |
United States | University of Utah | Salt Lake City | Utah |
United States | University of California, San Francisco | San Francisco | California |
Lead Sponsor | Collaborator |
---|---|
Clinuvel Pharmaceuticals Limited |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Time in Direct Sunlight Between 10:00-15:00 on Pain-free Days | The amount of direct sunlight exposure between 10:00 and 15:00 hours on days when no pain was experienced (e.g. 11-point Likert pain score of 0). Time was recorded in a patient dairy using 15 minute time blocks. The pain score is measured by the 11-point Likert Pain scale with minimum of 0 and maximum of 10. Likert Pain scale of 0 represents no pain and 10 represents worst imaginable pain. |
Daily for 6 months | |
Secondary | Maximum Severity of Phototoxic Reaction Experienced by Participants | The days on which the participant experienced pain as a result of phototoxic reactions (caused by exposure to natural light) was recorded in a study diary. On each day such a reaction occurred, the participant scored the level of pain using an 11-point Likert pain scale, with minimum of 0 and maximum of 10. The 11-point Likert pain scale with a value of 0 represents no pain and 10 represents worst imaginable pain. The maximum severity of a phototoxic reaction was determined by the highest daily 11-point Likert scale score that occurred during that phototoxic reaction. |
Daily for 6 months | |
Secondary | Quality of Life Measured by Participant Completed Questionnaire | Erythropoietic Protoporphyria Quality of Life Measure (EPP-QoL) is used to measure the quality of life of participants. The total EPP-QoL score ranges from 0 to 100, with a score of 0 as the worst quality of life and score of 100 as the best quality of life. |
Day 0, Day 60, Day 120, Day 180 | |
Secondary | Change of Total Protoporphyrin IX Level in Participants | This was an exploratory assessment only to analyze whether afamelanotide-induced change in sun exposure would result in a reduction of protoporphyrin IX. The changes of the Total Protoporphyrin IX Level (µg/dL) from Screening Visit (ITT Population) were measured between the two groups. The Protoporphyrin IX level is a laboratory parameter that is measured in specialist labs. |
Baseline, Day 60, Day 120, Day 180 | |
Secondary | Number of Participants With Phototoxic Reactions With Likert Severity Scores = 4 and = 7 | The number of participants who experienced phototoxic reactions with Likert severity scores = 4 and severity scores =7 were recorded. A derived endpoint was used. The number of participants who reported at least one phototoxic reaction with a Likert severity score of = 4 was recorded. For severity scores = 7, the number of patients who reported at least one phototoxic reaction with a Likert severity score of = 7 was recorded. The 11-point Likert pain scale ranges from minimum of 0 to maximum of 10. The 11-point Likert pain scale with a value of 0 represents no pain and 10 represents worst imaginable pain. |
Daily for 6 months | |
Secondary | Number of Phototoxic Reactions Experienced by Participants | The days on which the participant experienced pain as a result of phototoxic reactions (caused by exposure to natural light) was recorded in a study diary. On each day such a reaction occurred, the participant scored the level of pain using an 11-point Likert pain scale, with minimum of 0 and maximum of 10. The 11-point Likert pain scale with a value of 0 represents no pain and 10 represents worst imaginable pain. The number of phototoxic reactions was determined by counting the number of episodes on which participants report a 11-point Likert scale score of 4 or more for one or more consecutive days. |
Daily for 6 months | |
Secondary | Total Severity of Phototoxic Reactions Experienced by Participants Over the Entire Study | The days on which the participant experienced pain as a result of phototoxic reactions (caused by exposure to natural light) was recorded in a study diary. On each day such a reaction occurred, the participant scored the level of pain using an 11-point Likert pain scale, with minimum of 0 and maximum of 10. The 11-point Likert Pain scale with a value of 0 represents no pain and 10 represents worst imaginable pain. The total severity of phototoxic reactions was determined by the sum of daily 11-point Likert scale scores that occurred during phototoxic reactions. The overall sum of the severity per participant over the entire study was analyzed. The theoretical minimum score is 0 and the maximum possible score is 1800. |
Daily for 6 months. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00979745 -
Phase III Confirmatory Study in Erythropoietic Protoporphyria (EPP)
|
Phase 3 | |
Active, not recruiting |
NCT05308472 -
Study of Bitopertin to Evaluate the Safety, Tolerability, Efficacy, and PPIX Concentrations in Participants With EPP
|
Phase 2 | |
Completed |
NCT00004831 -
Study of Cysteine Hydrochloride for Erythropoietic Protoporphyria
|
N/A | |
Completed |
NCT05572125 -
Iron Therapy in Erythropoietic Protoporphyria
|
||
Completed |
NCT01605136 -
Phase III Confirmatory Study in Erythropoietic Protoporphyria
|
Phase 3 | |
Completed |
NCT01422915 -
Sorbent Therapy of the Cutaneous Porphyrias
|
Phase 2/Phase 3 | |
Completed |
NCT04053270 -
Multicentre Phase III Erythropoietic Protoporphyria Study
|
Phase 3 | |
Completed |
NCT00004940 -
Phase III Study of L-Cysteine in Patients With Erythropoietic Protoporphyria
|
Phase 3 | |
Recruiting |
NCT06388642 -
Pharmacokinetics of Afamelanotide in EPP Patients
|
Phase 1/Phase 2 | |
Recruiting |
NCT05020184 -
Effect of Oral Cimetidine in the Protoporphyrias
|
Phase 2 | |
Completed |
NCT01688895 -
Erythropoietic Protoporphyrias: Studies of the Natural History, Genotype-Phenotype Correlations, and Psychosocial Impact
|
||
Completed |
NCT04578496 -
A Safety Extension Study in Patients With Erythropoietic Protoporphyria (EPP)
|
Phase 3 | |
Recruiting |
NCT00206869 -
Does Exercise and Heat Increase the Lightsensibility in Patients With Erythropoietic Protoporphyria
|
N/A | |
Recruiting |
NCT05780840 -
Protection Against Visible Light by Dihydroxyacetone in Erythropoietic Protoporphyria
|
N/A | |
Completed |
NCT02979249 -
Oral Iron for Erythropoietic Protoporphyrias
|
N/A | |
Enrolling by invitation |
NCT05883748 -
Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP
|
Phase 2/Phase 3 | |
Completed |
NCT03682731 -
Light Exposure Patterns and Symptoms Among Patients With Erythropoietic Protoporphyria
|